ArticleBMC cancer2021

ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.

Ramadhan Karsono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.